全文获取类型
收费全文 | 17042篇 |
免费 | 1161篇 |
国内免费 | 91篇 |
专业分类
耳鼻咽喉 | 164篇 |
儿科学 | 322篇 |
妇产科学 | 271篇 |
基础医学 | 2375篇 |
口腔科学 | 175篇 |
临床医学 | 1614篇 |
内科学 | 4018篇 |
皮肤病学 | 383篇 |
神经病学 | 1768篇 |
特种医学 | 755篇 |
外科学 | 2879篇 |
综合类 | 44篇 |
一般理论 | 3篇 |
预防医学 | 784篇 |
眼科学 | 158篇 |
药学 | 1212篇 |
中国医学 | 26篇 |
肿瘤学 | 1343篇 |
出版年
2024年 | 13篇 |
2023年 | 130篇 |
2022年 | 236篇 |
2021年 | 585篇 |
2020年 | 305篇 |
2019年 | 528篇 |
2018年 | 607篇 |
2017年 | 417篇 |
2016年 | 421篇 |
2015年 | 505篇 |
2014年 | 760篇 |
2013年 | 884篇 |
2012年 | 1409篇 |
2011年 | 1441篇 |
2010年 | 821篇 |
2009年 | 767篇 |
2008年 | 1154篇 |
2007年 | 1118篇 |
2006年 | 1123篇 |
2005年 | 979篇 |
2004年 | 938篇 |
2003年 | 776篇 |
2002年 | 743篇 |
2001年 | 185篇 |
2000年 | 131篇 |
1999年 | 160篇 |
1998年 | 137篇 |
1997年 | 115篇 |
1996年 | 88篇 |
1995年 | 83篇 |
1994年 | 76篇 |
1993年 | 51篇 |
1992年 | 68篇 |
1991年 | 48篇 |
1990年 | 47篇 |
1989年 | 55篇 |
1988年 | 52篇 |
1987年 | 43篇 |
1986年 | 31篇 |
1985年 | 30篇 |
1984年 | 23篇 |
1983年 | 24篇 |
1982年 | 18篇 |
1975年 | 15篇 |
1974年 | 17篇 |
1972年 | 13篇 |
1971年 | 13篇 |
1970年 | 18篇 |
1969年 | 14篇 |
1968年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
5.
6.
7.
8.
9.
Thierry Patrice David Olivier Ludovic Bourre 《Journal of environmental pathology, toxicology and oncology》2006,25(1-2):467-485
Photodynamic therapy (PDT) is based on the selective light activation of an exogenously given drug to patients. PDT acts mainly on cell membranes either of neovascular endothelial cells or of cancer cells leading to cancer cell death. Six drugs are now marketed based on clinical assays in various indications, which showed a clear cost efficiency as compared to other classical procedures. PDT is easy to handle and can be performed in medical installations fitting the conditions of health care in developing countries. Its cost effectiveness could represent an appropriate solution to the increasing number of cancers of various origin. However despite all the clinical results now available, PDT development remains slow. The reasons for this situation include cost of development, intellectual property, and competition between pharmaceutical companies. 相似文献
10.
Anne Pavy-Le Traon Richard L Hughson Claire Thalamas Monique Galitsky Nelly Fabre Olivier Rascol Jean-Michel Senard 《Movement disorders》2006,21(12):2122-2126
Patients with multiple system atrophy (MSA) present large changes in blood pressure (BP) due to autonomic disturbances. We analyzed how this change may influence dynamic cerebral autoregulation (DCA). Simultaneous recordings of arterial BP (Finapres) and middle cerebral artery (MCA) blood flow velocity (BFV) (transcranial Doppler) were performed in 10 patients with MSA (61 +/- 12 yr of age) and 12 healthy volunteers (61 +/- 11 yr of age): cerebral BFV response to oscillations in mean BP was studied in the supine position by cross-spectral analysis of mean BP and mean MCA BFV. The DCA was also studied during the decrease in BP the first seconds when standing up from a sitting position by the assessment of the cerebrovascular resistance index (CR; mean BP/mean MCA BFV ratio). The MCA BFV/BP cross-spectral analysis showed a phase for the mid-frequency band (0.07-0.2 Hz) significantly larger in MSA, suggesting more active autoregulation in response to larger changes in BP. Changes in CR reflecting the rate of autoregulation, when standing did not differ between the two groups. These data suggest that dynamic cerebral autoregulation is preserved in MSA. 相似文献